90 related articles for article (PubMed ID: 9507074)
1. Identification of residues in the Gla-domain of human factor IX involved in the binding to conformation specific antibodies.
Wojcik EG; Cheung WF; van den Berg M; van der Linden IK; Stafford DW; Bertina RM
Biochim Biophys Acta; 1998 Jan; 1382(1):91-101. PubMed ID: 9507074
[TBL] [Abstract][Full Text] [Related]
2. Localization of a calcium-dependent epitope to the amino terminal region of the Gla domain of human factor IX.
Cheung WF; Stafford DW; Sugo T
Thromb Res; 1996 Jan; 81(1):65-73. PubMed ID: 8747521
[TBL] [Abstract][Full Text] [Related]
3. Discontinuous residues of factor IX constitute a surface for binding the anti-factor IX monoclonal antibody A-5.
Chang YJ; Wu HL; Hsu YC; Hamaguchi N; Shi GY; Shen MC; Lin SW
Thromb Res; 2003; 111(4-5):293-9. PubMed ID: 14693178
[TBL] [Abstract][Full Text] [Related]
4. Localization of the specific binding site for magnesium(II) ions in factor IX.
Sekiya F; Yoshida M; Yamashita T; Morita T
FEBS Lett; 1996 Sep; 392(3):205-8. PubMed ID: 8774845
[TBL] [Abstract][Full Text] [Related]
5. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa.
Liebman HA; Furie BC; Furie B
J Biol Chem; 1987 Jun; 262(16):7605-12. PubMed ID: 3108254
[TBL] [Abstract][Full Text] [Related]
6. Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation.
Wojcik EG; van den Berg M; van der Linden IK; Poort SR; Cupers R; Bertina RM
Biochem J; 1995 Nov; 311 ( Pt 3)(Pt 3):753-9. PubMed ID: 7487929
[TBL] [Abstract][Full Text] [Related]
7. The N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody.
Persson KE; Villoutreix BO; Thämlitz AM; Knobe KE; Stenflo J
J Biol Chem; 2002 Sep; 277(38):35616-24. PubMed ID: 12105230
[TBL] [Abstract][Full Text] [Related]
8. Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa.
Wojcik EG; Van Den Berg M; Poort SR; Bertina RM
Biochem J; 1997 May; 323 ( Pt 3)(Pt 3):629-36. PubMed ID: 9169594
[TBL] [Abstract][Full Text] [Related]
9. gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function.
Gillis S; Furie BC; Furie B; Patel H; Huberty MC; Switzer M; Foster WB; Scoble HA; Bond MD
Protein Sci; 1997 Jan; 6(1):185-96. PubMed ID: 9007991
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody.
Huang M; Furie BC; Furie B
J Biol Chem; 2004 Apr; 279(14):14338-46. PubMed ID: 14722079
[TBL] [Abstract][Full Text] [Related]
11. Derivatives of blood coagulation factor IX contain a high affinity Ca2+-binding site that lacks gamma-carboxyglutamic acid.
Morita T; Isaacs BS; Esmon CT; Johnson AE
J Biol Chem; 1984 May; 259(9):5698-704. PubMed ID: 6425296
[TBL] [Abstract][Full Text] [Related]
12. The metal-dependent conformational changes in factor IX associated with phospholipid binding. Studies using antibodies against a synthetic peptide and chemical modification of factor IX.
Liebman HA
Eur J Biochem; 1993 Mar; 212(2):339-45. PubMed ID: 7680311
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the tertiary structure and function of coagulation factor IX by magnesium (II) ions.
Sekiya F; Yamashita T; Atoda H; Komiyama Y; Morita T
J Biol Chem; 1995 Jun; 270(24):14325-31. PubMed ID: 7782291
[TBL] [Abstract][Full Text] [Related]
14. Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX.
Cheung WF; Wolberg AS; Stafford DW; Smith KJ
Thromb Res; 1995 Dec; 80(5):419-27. PubMed ID: 8588203
[TBL] [Abstract][Full Text] [Related]
15. Properties of recombinant chimeric human protein C and activated protein C containing the gamma-carboxyglutamic acid and trailing helical stack domains of protein C replaced by those of human coagulation factor IX.
Christiansen WT; Castellino FJ
Biochemistry; 1994 May; 33(19):5901-11. PubMed ID: 8180219
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm.
Hamaguchi N; Roberts H; Stafford DW
Biochemistry; 1993 Jun; 32(25):6324-9. PubMed ID: 8518277
[TBL] [Abstract][Full Text] [Related]
17. Influence of specific gamma-carboxyglutamic acid residues on the integrity of the calcium-dependent conformation of human protein C.
Zhang L; Castellino FJ
J Biol Chem; 1992 Dec; 267(36):26078-84. PubMed ID: 1464619
[TBL] [Abstract][Full Text] [Related]
18. Characterization of gamma-carboxyglutamic acid residue 21 of human factor IX.
Wolberg AS; Li L; Cheung WF; Hamaguchi N; Pedersen LG; Stafford DW
Biochemistry; 1996 Aug; 35(32):10321-7. PubMed ID: 8756687
[TBL] [Abstract][Full Text] [Related]
19. The binding of human factor IX to endothelial cells is mediated by residues 3-11.
Cheung WF; Hamaguchi N; Smith KJ; Stafford DW
J Biol Chem; 1992 Oct; 267(29):20529-31. PubMed ID: 1400370
[TBL] [Abstract][Full Text] [Related]
20. Anti-human factor IX monoclonal antibodies specific for calcium ion-induced conformations.
Sugo T; Mizuguchi J; Kamikubo Y; Matsuda M
Thromb Res; 1990 Jun; 58(6):603-14. PubMed ID: 2385830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
